Posts

From Debt to Acceptable Prices: Roche CEO Lists 3 Reasons for Sitting Out Big Pharma M&A Spree

on

Novo Holdings Assets Shrink by a Third Due to Novo Nordisk's Falling Share Price

on

CMS Unveils Negotiated Prices for Ozempic, Wegovy, and Other Drugs in Second Round of IRA Talks

on

Trump Announces Sweeping Cost Cuts on Lilly and Novo Weight Loss Drugs in Exchange for Medicare Coverage

on

Trump Administration Teases MFN Drug Pricing Rule as Commitment Deadline Looms for Companies

on

Bristol Myers Squibb to Launch Schizophrenia Drug Cobenfy in UK at US Price

on

Novo Nordisk's Leadership Shakeup and Wider Implications; Ex-FDA Official Takes Regulatory Role at GSK

on

Replimune's Shares Plunge After FDA Rejects Melanoma Drug Application

on

FDA Commissioner Makary Proposes Fast-Track Drug Review Vouchers Tied to Lower US Prices, Without Detailing Criteria

on

Senate Drops Orphan Cures Act from Trump's Tax Bill, Dealing Setback to Biopharma

on

Moderna Shares Fall as Company Withdraws Flu/COVID-19 Combination Vaccine Application

on

'Go ahead and do it': Top RFK Jr. Deputy Dares Drugmakers Over Threats to Pull Manufacturing Amid Price Pressure

on

Trump signs sweeping executive order to cut US drug prices by 'up to 90%'

on

From deal to disaster: Drugmakers face a changed Washington as Trump embraces most favored nation prices

on

Regeneron loses bid to fend off DOJ fight over Eylea Medicare payments

on

Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with other nations

on

Trump pledges his support for a change to the IRA long sought by drugmakers

on

Pharma's wins and losses in Trump's sprawling executive order on drug prices

on

Trump's Looming Pharmaceutical Tariffs: Uncertainty and Potential Impact

on

IRA round 2 begins as drugmakers sign on to price negotiation process with CMS

on